For broader research context on nootropic compounds, including comparative stacks, cycling considerations, and interaction notes, see the Complete Nootropic Cheat Sheet.
What Is Cerebrolysin?
Cerebrolysin is a parenterally administered neuropeptide preparation derived from pig brain tissue through controlled enzymatic proteolysis. It is a mixture of small bioactive peptides (molecular weight below 10,000 Da) and free amino acids that together produce neurotrophic effects similar to endogenous NGF, BDNF, CNTF, and other neurotrophins. It is approved for clinical use in cognitive disorders and stroke recovery in over 40 countries.
Mechanism of Action
Cerebrolysin produces its effects through multiple mechanisms: it mimics endogenous neurotrophic factors by activating TrkA, TrkB, and p75NTR receptors on neurons; reduces excitotoxic glutamate signaling; protects neurons from oxidative stress; and promotes neuroplasticity by stimulating synaptogenesis and dendritic arborization. Its peptide fractions can cross the blood-brain barrier, allowing systemic administration to produce central neurotrophic effects.
Clinical Evidence
Multiple RCTs have demonstrated improvements in global clinical status, cognition, and ADL function in mild-to-moderate Alzheimer's patients. In stroke, the CASTA trial documented improvements in early neurological recovery. These represent some of the most robust clinical datasets for any neurotrophic peptide preparation.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials
Bornstein, N.M., Guekht, A., Vester, J., et al., 2018, Neurological Sciences - How to use Cerebrolysin®
Ever Pharma, N/A, N/A - Efficacy and Safety of Cerebrolysin for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials
Zhang, D., Dong, Y., Li, Y., et al., 2017, BioMed Research International - Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial
Muresanu, D.F., Heiss, W.D., Hoemberg, V., et al., 2020, Neurological Sciences - Cerebrolysin in Patients with TBI: Systematic Review and Meta-Analysis
Kojder, K., Sykutera, M., Gold, P., et al., 2023, Brain Sciences - Randomized, placebo-controlled, double-blind, pilot trial to investigate safety and efficacy of Cerebrolysin in patients with aneurysmal subarachnoid hemorrhage
Woo, P.Y.M., Ho, J.W.K., Tse, T.P.K., et al., 2020, BMC Neurology - Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials
Gauthier, S., Proano, J.V., Jia, J., et al., 2015, Dementia and Geriatric Cognitive Disorders - Cerebrolysin for vascular dementia
Cui, S., Cui, L., Mutz, J., et al., 2019, Cochrane Database of Systematic Reviews - Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes
Fiani, B., Barthelmass, E., Bosco, A., et al., 2021, Neurological Sciences - Efficacy, safety, and cost-effectiveness analysis of Cerebrolysin in acute ischemic stroke: A rapid health technology assessment
Li, J., Yu, Q., Zhang, L., et al., 2024, Medicine (Baltimore) - Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial
Guekht, A.B., Moessler, H., Novak, P.H., et al., 2011, Journal of Stroke and Cerebrovascular Diseases